Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oncorus, Inc.ONCR · Entity 112213 | Director | June 23, 2022 | June 24, 2022 |
| TREVENA INCTRVN · Entity 85383 | Director | June 13, 2024 | June 14, 2024 |
| VACCINEX, INC.VCNX · Entity 9673 | Director | May 10, 2024 | May 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oncorus, Inc.
Report date June 23, 2022 · Filed June 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2032-06-23 | Direct | 12,500 |
Reported balance
After 2022-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-23 · Grant · Acquired 12,500 · Balance 12,500 F1: The option shall vest in twelve (12) equal monthly installments commencing on July 23, 2022, subject to the Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest in twelve (12) equal monthly installments commencing on July 23, 2022, subject to the Reporting Person continuing to provide service through each such date.
TREVENA INC
Report date June 13, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40 · Expires 2034-06-13 | Direct | 13,700 |
Reported balance
After 2024-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-13 · Grant · Acquired 13,700 · Balance 13,700 F1: The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date.
VACCINEX, INC.
Report date May 10, 2024 · Filed May 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.75 | Direct | 10,108 |
Reported balance
After 2024-05-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-05-10 · Grant · Acquired 10,108 · Balance 10,108 F7: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2,856.00 · Expires 2027-09-15 | Direct | 30 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance 30 F1: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1,633.80 | Direct | 36 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 36 F2: This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $829.50 | Direct | 74 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 74 F3: This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $451.50 | Direct | 136 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 136 F4: This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $235.20 | Direct | 253 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 253 F5: This option expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $86.10 | Direct | 684 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 684 F6: This option expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable in full as of the date of this report.
F2: This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.
F3: This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first.
F4: This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first.
F5: This option expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first.
F6: This option expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first.
F7: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AKCEA THERAPEUTICS, INC.
Report date October 12, 2020 · Filed October 13, 2020
Section 16 reporting ended · disclosed 2020-10-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.14 · Expires 2030-04-12 | Direct | 0 |
Reported balance
After 2020-10-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-10-12 · Disposition to issuer · Disposed 26,400 · Balance 0 F1: This option, which provided for vesting of the shares on April 13, 2021, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $53,064.00, representing the difference between the exercise price of the option and the acquisition price of $18.15. |
Filing footnotes · ownership attribution and instrument terms
F1: This option, which provided for vesting of the shares on April 13, 2021, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $53,064.00, representing the difference between the exercise price of the option and the acquisition price of $18.15.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2024 Filed Jun 14, 2024 21:40 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 13,700 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001062993-24-012666 · form4.xml · derivative · entry 1 Yanni Barbara · CIK 0001610561 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,700 Underlying: Common Stock · 13,700 shares Expires 2034-06-13 F1 · derivative.exercise_date: The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| May 10, 2024 Filed May 14, 2024 16:33 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 10,108 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001062993-24-010184 · form4.xml · derivative · entry 7 Yanni Barbara · CIK 0001610561 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,108 Underlying: Common Stock · 10,108 shares Expires not disclosed F7 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:38 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 13,700 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001062993-23-013837 · form4.xml · derivative · entry 1 Yanni Barbara · CIK 0001610561 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,700 Underlying: Common Stock · 13,700 shares Expires 2033-06-15 F1 · derivative.exercise_date: The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| May 11, 2023 Filed May 15, 2023 16:31 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 143,848 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001062993-23-011110 · form4.xml · derivative · entry 6 Yanni Barbara · CIK 0001610561 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,848 Underlying: Common Stock · 143,848 shares Expires not disclosed F6 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 06:57 UTC | Oncorus, Inc. ONCR · Entity 112213 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001209191-22-039092 · doc4.xml · derivative · entry 1 Yanni Barbara · CIK 0001610561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2032-06-23 F1 · derivative.exercise_date: The option shall vest in twelve (12) equal monthly installments commencing on July 23, 2022, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 21:25 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001062993-22-014806 · form4.xml · derivative · entry 1 Yanni Barbara · CIK 0001610561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| May 12, 2022 Filed May 13, 2022 16:39 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 53,254 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001062993-22-012385 · form4.xml · derivative · entry 5 Yanni Barbara · CIK 0001610561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,254 Underlying: Common Stock · 53,254 shares Expires not disclosed F5 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 16:52 UTC | Oncorus, Inc. ONCR · Entity 112213 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $12.82 | $0.00 |
DisclosureSEC source: 0001209191-21-048507 · doc4.xml · derivative · entry 1 Yanni Barbara · CIK 0001610561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-07-26 F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares subject to the option shall vest each month commencing on August 27, 2021, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 21:02 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 68,577 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001429560-21-000008 · edgar.xml · derivative · entry 1 Yanni Barbara · CIK 0001610561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,577 Underlying: Common Stock · 68,577 shares Expires 2031-05-28 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| May 11, 2021 Filed May 12, 2021 16:25 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 28,586 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0000891839-21-000138 · edgar.xml · derivative · entry 4 Yanni Barbara · CIK 0001610561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,586 Underlying: Common Stock · 28,586 shares Expires not disclosed F4 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| October 12, 2020 Filed Oct 13, 2020 15:50 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Disposition to issuerStock Option (right to buy) · Derivative | 26,400 | $2.01 Strike: $16.14 | $53,064.00 |
DisclosureSEC source: 0001209191-20-054612 · doc4.xml · derivative · entry 1 Yanni Barbara · CIK 0001610561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,400 shares Expires 2030-04-12 F1 · derivative.exercise_date: This option, which provided for vesting of the shares on April 13, 2021, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $53,064.00, representing the difference between the exercise price of the option and the acquisition price of $18.15. Read SEC document |
| May 14, 2020 Filed May 18, 2020 16:19 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 15,679 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0000891839-20-000118 · edgar.xml · derivative · entry 3 Yanni Barbara · CIK 0001610561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,679 Underlying: Common Stock · 15,679 shares Expires not disclosed F3 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| May 13, 2020 Filed May 15, 2020 21:29 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 64,103 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001209191-20-029791 · doc4.xml · derivative · entry 1 Yanni Barbara · CIK 0001610561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,103 Underlying: Common Stock · 64,103 shares Expires 2030-05-13 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 17:09 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantStock Option (right to buy) · Derivative | 26,400 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0001209191-20-024502 · doc4.xml · derivative · entry 1 Yanni Barbara · CIK 0001610561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2030-04-12 F1 · derivative.exercise_date: The shares vest on the 12-month anniversary of the date of grant. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 16:35 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantStock Option (right to buy) · Derivative | 53,000 | $0.00 Strike: $19.30 | $0.00 |
DisclosureSEC source: 0001209191-19-060662 · doc4.xml · derivative · entry 1 Yanni Barbara · CIK 0001610561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Stock · 53,000 shares Expires 2029-12-12 F1 · derivative.exercise_date: The shares vest over a four year period in equal annual installments beginning on December 13, 2019. Read SEC document |
| May 16, 2019 Filed May 16, 2019 21:35 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001209191-19-030532 · doc4.xml · derivative · entry 1 Yanni Barbara · CIK 0001610561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-05-16 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| May 15, 2019 Filed May 17, 2019 16:37 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 7,718 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0000891839-19-000068 · edgar.xml · derivative · entry 2 Yanni Barbara · CIK 0001610561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,718 Underlying: Common Stock · 7,718 shares Expires not disclosed F2 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| May 16, 2018 Filed May 17, 2018 21:11 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001209191-18-031040 · doc4.xml · derivative · entry 1 Yanni Barbara · CIK 0001610561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-05-16 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| May 17, 2017 Filed Jun 6, 2017 20:46 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001209191-17-038146 · doc4.xml · derivative · entry 1 Yanni Barbara · CIK 0001610561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-17 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.